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Following primary infection with human immunodeficiency virus type-1 (HIV-1), macrophages are thought to play an important role, as they
are one of the first target cells the virus encounters and can also sustain a significant production of viruses over extended periods of time. While the
interaction between the primary cellular receptor CD4 and the virus-encoded external envelope glycoprotein gp120 initiates the infection process,
it has been suggested that various host factors are exploited by HIV-1 to facilitate adsorption onto the cell surface. Macrophages and other cells
found at the infection site can secrete a soluble mammalian lectin, galectin-1, which binds to β-galactoside residues through its carbohydrate
recognition domain. Being a dimer, galectin-1 can cross-link ligands expressed on different constituents to mediate adhesion between cells or
between cells and pathogens. We report here that galectin-1, but not galectin-3, increased HIV-1 infectivity in monocyte-derived macrophages
(MDMs). This phenomenon was likely due to an enhancement of virus adsorption kinetics, which facilitates HIV-1 entry. The fusion inhibitors T-20
and TAK779 remained effective at reducing infection even in the presence of galectin-1, indicating that the galectin-1-mediated effect is occurring at a
step prior to fusion. Together, our data suggest that galectin-1 can facilitate HIV-1 infection in MDMs by promoting early events of the virus
replicative cycle (i.e. adsorption).
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It has been estimated that the human immunodeficiency
virus type-1 (HIV-1) pandemic now affects more than 40 million
people and has caused more than 20 million deaths worldwide.
This retrovirus preferentially infects activated CD4+ T lym-
phocytes and macrophages through a pH-independent fusion
process involving an association between the viral transmem-
brane and surface proteins gp41 and gp120 with a complex
made of the cellular surface protein CD4 and a coreceptor of the
chemokine receptor family, generally CCR5 or CXCR4. Fol-⁎ Corresponding authors. Laboratory of Human Immuno-Retrovirology and
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doi:10.1016/j.virol.2007.09.034lowing primary infection, continuous viral replication and its
associated CD4+ T cell toxicity slowly but relentlessly cripple
the host's ability to mount an efficient immune response,
leading to the appearance of a large variety of symptoms, better
known as acquired immunodeficiency syndrome (AIDS).
The majority of mammalian cell surface molecules, as well as
those of enveloped virus, are heavily glycosylated. Specific
sugar sequences presented by the glycans of these glycoproteins
can be recognized by a variety of glycan-binding proteins called
lectins. One of such lectin families, galectins, has been recently
suggested to play functional roles in various immune response
processes through binding to host surface glycoproteins
(Almkvist et al., 2002; Barrionuevo et al., 2007; Baum et al.,
1995; Correa et al., 2003; Gauthier et al., 2002; He and Baum,
2004; Perillo et al., 1995; Rabinovich et al., 1998, 2002a,b; Sato,
2002; Sato and Nieminen, 2004). For example, galectin-1
belongs to the galectin family, β-galactoside-binding proteins,
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drate recognition domain (CRD). Up to 14 galectins (galectin-1–
14) have been found in mammals so far, which can be sub-
divided into three categories depending on the presentation of
CRD domains: prototype, tandem-repeat and chimera (Hira-
bayashi and Kasai, 1993). Some galectins contain one CRD
(prototype), and exist as monomers (galectin-5, 7, 10) or dimers
(galectin-1, 2, 11, 13, 14), other galectins, such as galectin-4, 6,
8, 9 and 12, contain two CRD connected by a short linker region
(tandem repeat) (Hirabayashi and Kasai, 1993). In contrast,
galectin-3 uniquely occurs as a chimeric protein with one CRD
and an additional non-CRD domain, which is involved in the
oligomerization of galectin-3 (Hirabayashi and Kasai, 1993;
Nieminen et al., 2007). Galectin-1 expression has been reported
in thymus and lymphoid parenchymal epithelial cells, endothe-
lial cells, trophoblasts, activated T cells, macrophages, activated
B cells, follicular dendritic cells and CD4+CD25+ regulatory T
cells (Baum et al., 1995; Blaser et al., 1998; Dettin et al., 2003;
Garin et al., 2007; Jeschke et al., 2004; Rabinovich et al., 1996;
Stillman et al., 2006; Zuniga et al., 2001a). We recently found
that human tonsil lymphoid tissues contain∼16 μMof galectin-
1 (Ouellet et al., 2005). Galectins are synthesized as cytosolic
proteins, thereby the export of galectins into extracellular space
is regulated (Cooper and Barondes, 1990; Hughes, 1999; Sato et
al., 1993; Sato and Hughes, 1994), while their biological
significance remains speculative (Hughes, 1999; Rabinovich et
al., 2007; Sato, 2002; Sato and Nieminen, 2004). Indeed,
galectin-1 is actively secreted by activated B cells, T cells and
macrophages and certain epithelial cells (without compromising
membrane integrity) through a “leaderless” secretory pathway
(Baum et al., 1995; Blaser et al., 1998; Garin et al., 2007;
Gauthier et al., 2002; Rabinovich et al., 1998; Zuniga et al.,
2001b), which is also used by fibroblast growth factors and IL-1
(Hughes, 1999; Nickel, 2003, 2005; Oppenheim et al., 2007).
Due to their multivalent nature, galectins can cross-link different
constituents, acting as adhesion molecules (Baum et al., 1995;
Gauthier et al., 2002; Hughes, 2001; Rabinovich et al., 2002a;
Rabinovich and Gruppi, 2005; Sato, 2002; Sato and Nieminen,
2004). We have previously found that one member of the
galectin family, galectin-1 (Gal-1), can potentiate infection of
human tonsilar tissues and primary human peripheral CD4+ T
cells by X4-tropic isolates of HIV-1 (Ouellet et al., 2005). Gal-1
can stabilize attachment of HIV-1 particles onto CD4+ T cells
thereby facilitating the infection of such susceptible cells. Our
previous study was the first demonstration of the impact of Gal-1
in the HIV-1 life cycle, but it mainly reflected the role of Gal-1 in
the later stages of the infection, when the virus has reached the
secondary lymphoid organs. However, there is still no inform-
ative data on the possible involvement of Gal-1 during primary
infection. The value of such results resides in the possibility of
developing strategies aimed at reducing the occurrence of initial
infection.
Infection of macrophages by R5-tropic isolates of HIV-1
may play an important role during the early stages of infection
(Noursadeghi et al., 2006). Indeed, macrophages found in the
genital and intestinal tracts are mainly exposed to R5-tropic
virions during primary infection (Brumme et al., 2005), pos-sibly because the mucosal barrier restricts the transmission of
X4 strains (Margolis and Shattock, 2006; Meng et al., 2002).
Some studies also revealed that recently infected individuals
predominantly harbor R5 isolates of HIV-1 (Koot et al., 1996;
Zhang et al., 1998). Macrophages are also thought to play a role
in later stages of infection because they are inherently resistant
to the cytopathic effects of the virus, and are thus considered to
be a stable and long-lived cellular reservoir (Verani et al., 2005).
Moreover, their interplay with CD4+ T lymphocytes as profes-
sional antigen presenting cells may facilitate trans or cis infec-
tion of this cell type through their direct contact and activation
(Verani et al., 2005). As macrophages are thought to be im-
portant actors in the pathogenesis of HIV-1 infection, and as
they also express and secrete Gal-1 following their activation
(Correa et al., 2003), it is essential to extend our initial obser-
vations to this particular cell type.
This study thus focuses on the role of Gal-1 in the infection
process of monocyte-derived macrophages (MDMs) by R5-
tropic variants of HIV-1. We report here that exogenous addition
of Gal-1 to MDMs enhances HIV-1 infection possibly through
an increase in viral binding kinetics. Interestingly, the antiviral
potency of fusion inhibitors targeting gp41 (T-20) and CCR5
(TAK779) was not affected by Gal-1, thus indicating that this
soluble factor is affecting the HIV-1 life cycle at a step prior to
fusion. The possible implications of this set of results could
prove to be important for the efficient use of the already available
antiretroviral drugs.
Results
Galectin-1, but not galectin-3, promotes HIV-1 infection in
MDMs
MDMs were initially infected with recombinant luciferase-
encoding reporter viruses that were pseudotyped with the R5-
tropic JR-FL envelope. This experimental setup allows a rapid,
accurate and quantitative evaluation of single-cycle infection
events through measurement of cell-associated luciferase
activity following infection. As shown in Fig. 1A, the presence
of Gal-1 significantly increased virus-induced luciferase
activity. This Gal-1-mediated augmentation in virus replication
was dose-dependent up to a 4 μM final concentration of Gal-1
(data not shown). In order to assess the specificity of Gal-1
action, further infection experiments were performed in the
presence of another member of the galectin family, namely
galectin-3 (Gal-3). Interestingly, infection of MDMs by the
reporter virus remained unaffected when it was performed in the
presence of Gal-3 (Fig. 1A). These results suggest that the Gal-
1-mediated enhancing effect on HIV-1 infection is specific and
is not a general phenomenon that can take place with all mem-
bers of the galectin family.
Although the initial series of investigations is informative, it
is important to emphasize that such experiments have been
performed with pseudotyped, replication-incompetent, reporter
viruses produced in a human cell line, which is not considered
as a natural cellular reservoir for HIV-1 (i.e. 293T cells). More-
over, it is well established that HIV-1 acquires a vast array of
Fig. 1. Gal-1 increases HIV-1 infection in MDMs. (A) MDMs (5×104) were
incubated for 1 h at 37 °Cwith reporter viruses pseudotypedwith JR-FL envelope
(1×104 TCID50) produced in 293T cells in the presence of 2 μM of Gal-1, Gal-3
or equal volumes of the appropriate control. Cells where then washed and
incubated for 5 days at 37 °C before luciferase activity was assayed as described
in Materials and methods. (B) Similar experiments were carried out using fully
competent NL4-3/BaL virions produced in MDMs (5×102 TCID50). Cell-free
supernatants were harvested every 3 days and the p24 content was assayed as
described inMaterials andmethods. Data shown correspond to themeans±SD of
triplicate samples and are representative of three independent experiments.
(C) MDMs were infected 3 days with reporter viruses pseudotyped with VSV-G
env. Cells were then washed twice prior to adding of 2 μM of Gal-1 or equal
volumes of the appropriate control. Cells were then incubated for 1 to 24 h before
luciferase activity was assayed as described in Materials and methods.
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(Tremblay et al., 1998). Since the majority of surface proteins
on mammalian cells are glycosylated to increase their stability
and lock-in their conformation, viruses budding from these cells
will carry such host-derived glycosylated proteins on their
surface. While the glycosylation patterns of surface proteins
are protein-specific, their patterns can vary, to some extent,
depending on the cell-type and cell status (e.g. resting versus
activated, apoptotic, etc.) (Ohtsubo and Marth, 2006). Thus,
viruses produced in different cell types might acquire differentglycosylation patterns that could, in turn, have an impact on the
ability of Gal-1 to affect viral replication. Acknowledging this
possibility, the experimental setup described above was re-
peated, but this time using replication-competent R5-tropic
virions (i.e. NL4-3/BaL) harvested from acutely infected
MDMs. Data shown in Fig. 1B demonstrate that replication of
fully competent virus was augmented by the presence of Gal-1.
Together, the data suggest that Gal-1 facilitates infection of
MDMs by R5-tropic viruses. Additional studies revealed that
Gal-1 was unable to induce transcription from the HIV-1 regu-
latory elements (i.e. long terminal region/LTR) (Fig. 1C).
Therefore it can be concluded that the Gal-1-dependent effect on
HIV-1 replication is not due to signal transduction events that
can in turn promote HIV-1 LTR-driven activity.
Given the reported capacity of Gal-1 to cross-link ligands
expressed on different constituents (Baum et al., 1995; Gauthier
et al., 2002; Hughes, 2001; Rabinovich et al., 2002a;
Rabinovich and Gruppi, 2005; Sato, 2002; Sato and Nieminen,
2004) and its inability to drive HIV-1 LTR-driven gene
expression, it can be proposed that Gal-1 favors the first steps
in the HIV-1 replicative cycle by promoting the initial
interactions between the virus and the surface of target cells,
thereby facilitating viral entry. Adsorption of HIV-1 particles on
MDMs was thus assessed by measuring the cell-associated p24
levels following incubation for 1 h at 37 °C in the presence or
absence of 2 μM of Gal-1 or Gal-3 as described in Materials and
methods. As our experiments are performed at 37 °C, we refer
to it as an adsorption experiment. Adsorption includes virus that
bind and enter the cell through fusion or endocytosis. We chose
to proceed this way to better approximate the initial steps of
HIV-1 infection in vivo. As shown in Fig. 2A, virus adsorption
was significantly enhanced upon addition of Gal-1 (i.e. 9-fold
increase) but not Gal-3 (data not shown). The Gal-1-mediated
enhancement of HIV-1 adsorption was totally abolished by
lactose, which competes for the CRD of Gal-1 and acts as an
antagonist of this soluble β-galactoside-binding protein. When
the incubation period was extended to 6 h, cell-associated p24
levels in the absence of Gal-1 became comparable to those in
the presence of Gal-1 (Fig. 2B). This observation suggests that
Gal-1 accelerates the kinetics of the initial steps of HIV-1
replication. The Gal-1-mediated enhancement of HIV-1 adsorp-
tion was also observed when experiments were conducted with
X4-using virus (i.e. NL4-3 strain) (data not shown). This result
suggests that the increased adsorption observed is independent
of specific co-receptors. Given that our observations led us to
propose that virus adsorption occurred with faster kinetics in the
presence of Gal-1, we next investigated the level of viral
internalization in these cells in the presence or absence of Gal-1.
MDMs were incubated with NL4-3/BaL and increasing concen-
trations of Gal-1 (0 to 4 μM) for 1 h at 37 °C, in the presence or
absence of 50 mM of lactose. Unbound virus particles and those
that bound but did not enter the cells were removed by a trypsin
treatment as published previously (Tardif and Tremblay,
2005a,b). Results depicted in Fig. 2C demonstrate that virus
internalization was promoted in a dose-dependent manner by
Gal-1 (i.e. 2.5-fold increase in presence of 4 μM Gal-1; 1070±
75 versus 440±34 pg/ml). As seen with adsorption assays, this
Fig. 2. Adsorption and internalization of HIV-1 are promoted by Gal-1. (A) MDMs (5×104) were incubated for 1 h at 37 °C with fully competent NL4-3/BaL viruses
(10 ng of p24) in the presence of Gal-1 (2 μM) or mock preparations. Lactose (50 mM) was also added to some samples. Cells were then washed twice and the p24
content was assayed in lysed cells as described in Materials and methods. (B) MDMs (5×105) were incubated for 6 h at 37 °C with fully competent NL4-3/BaL viruses
(10 ng of p24) in the presence of Gal-1 (2 μM) or mock preparations. Cells were then washed twice and the p24 content was assayed in lysed cells as described in
Materials and methods. (C) MDMs (5×104) were incubated for 1 h at 37 °C with fully competent NL4-3/BaL viruses (10 ng of p24) in the presence of increasing
concentrations of Gal-1 or mock preparations. Lactose (50 mM) was also added to some samples. Next, cells were washed twice, treated with trypsin to remove
uninternalized virions and washed again twice. Finally, the p24 content was estimated as described in Materials and methods. (D) Similar studies were performed with
the fusion inhibitors T-20 (10 μg/ml) and TAK779 (100 μM). Data shown correspond to the means±SD of triplicate samples and are representative of three
independent experiments.
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order to confirm these results using a different experimental
strategy to remove bound but uninternalized viruses, we also
performed acid washes instead of trypsin treatment as described
previously (Vidricaire and Tremblay, 2005). Similar observa-
tions were made when using this method (data not shown),
which confirm that Gal-1 is affecting the earliest step in the HIV-
1 replicative cycle (i.e. adsorption).
The Gal-1-mediated increase in virus internalization could
be due to an enhancement in virus-mediated fusion and/or an
augmentation in HIV-1 entry through an endocytic process
such as macropinocytosis. We thus performed additional entry
assays, but this time in the presence of the fusion inhibitors T-20
and TAK779, which are targeting different actors of the
infection process. T-20 prevents fusion between virus and cell
membranes by binding to the viral fusion peptide of gp41,
whereas TAK779 is a chemical antagonist of CCR5 that inhibits
its interaction with the V3-loop of gp120 after it has bound to
CD4. These two inhibitors act directly on the essential inter-
actions required for the fusion of viral and cellular membranes.
Results illustrated in Fig. 2D indicate that, at the doses which
gave maximal inhibition of HIV-1 entry in CD4+ T cells (Tardif
and Tremblay, 2005a), HIV-1 internalization within MDMs,regardless of the presence or the absence of Gal-1, was not
affected by either T-20 or TAK779. These data suggest that, at
least under these experimental conditions, the gp41-mediated
membrane fusion events do not contribute significantly to the
process of HIV-1 internalization into MDMs.
Galectin-1 does not reduce the overall sensitivity of HIV-1 to
fusion inhibitors
Our previous report in CD4+ T lymphocytes indicates that
T-20 efficiently inhibits Gal-1-promoted viral replication,
suggesting that Gal-1 facilitates initial adsorption of X4-tropic
HIV-1 to CD4+ T lymphocytes, but not the following membrane
fusion step (Ouellet et al., 2005). In the case of MDMs, the data
presented above suggest that the fusion inhibitors T-20 and
TAK779 exhibit a limited capacity to reduce viral internaliza-
tion, which was significantly increased by Gal-1, possibly
through an increase of adsorption kinetics of the virus. There-
fore, we next studied whether these fusion inhibitors can
effectively limit infection ofMDMs byHIV-1. In the presence of
Gal-1, HIV-1 infection of MDMs was still detectable even at
high doses of T-20 or TAK779 due to the Gal-1-mediated
increase in HIV-1 infection (Figs. 3A and B). However, the
Fig. 3. Gal-1 does not decrease HIV-1 sensitivity to neutralization by fusion inhibitors. MDMs (5×104) were incubated for 1 h at 37 °C with reporter viruses
pseudotyped with JR-FL envelope (1×104 TCID50) in the presence of Gal-1 (2 μM) or PBS in combination with increasing concentrations of either T-20 (A and C) or
TAK779 (B and D). Cells were then washed twice and incubated for 5 days at 37 °C before luciferase activity was assayed as described in Materials and methods. The
results are presented as raw infection levels measured by luciferase activity assays (A, B) or as percentages of inhibition by a given concentration of the tested fusion
inhibitors with respect to the virus-infected samples that were left untreated with T-20 or TAK779 (C, D). The data shown represent the means±SD of triplicate
samples and are representative of three independent experiments.
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by T-20 were comparable whether the cells were treated or not
with 2 μM of Gal-1 (Fig. 3C). Similar observations were made
when experiments were carried out in the presence of TAK779
(Fig. 3D). Indeed, the calculated IC50 are 37 and 41 ng/ml for
T-20 and 0.028 and 0.030 nM for TAK779, in the presence and
absence of 2 μM of Gal-1. Together, the data suggest that
although Gal-1 significantly increased viral internalization and
infection in MDMs, the relative efficiency of the tested fusion
inhibitors was unaffected by Gal-1, even if they fail to limit
viral entry.
Discussion
Several lines of evidence imply that galectins participate in
the immune response, both as immunomodulators and mole-
cules that facilitate pathogen-host cell interactions (Kohatsu
et al., 2006; Mey et al., 1996; Rabinovich and Gruppi, 2005;
Sato, 2002; Sato and Nieminen, 2004). In addition, recent
works suggest that galectins could facilitate pathogen internal-
ization in phagocytic cells, such as macrophages (Pelletier et al.,
2003; van den Berg et al., 2004). However, there is very few, if
any, information concerning the roles of galectins in viral in-
fection, even though many enveloped virus express glycopro-
teins on their surface. We have recently reported that Gal-1 canincrease adsorption of X4-using isolates of HIV-1 onto CD4+ T
lymphocytes, thus enhancing the overall infection process
(Ouellet et al., 2005). This observation is in line with previous
studies showing that some galectins can act as adhesion mole-
cules by cross-linking surface ligands expressed on pathogens
and their target cells (Ouellet et al., 2005; Pelletier et al., 2003;
Rabinovich and Gruppi, 2005; Sato, 2002). Results depicted in
the present work therefore represent additional evidence of the
specific cross-linking capacity of galectins and suggest that
Gal-1 can modulate sexual transmission of HIV-1 through
enhancement of viral adsorption kinetics on diverse target
cells' surface. Interestingly, another type of galectin, Gal-3,
displayed no effect on HIV-1 adsorption, entry and infection in
a similar context, even though both Gal-1 and Gal-3 bind
efficiently to macrophages (Camby et al., 2006; Dumic et al.,
2006). This is in contrast to its ability to facilitate the in-
teraction between parasites and macrophages (Pelletier et al.,
2003; van den Berg et al., 2004). Likely due to structural
differences between Gal-1 and Gal-3, both in their CRDs and in
its presentation, some (but not all) of the ligands of
macrophages preferentially bind to galectin-1. In addition, it
is possible that the affinities of those galectins for HIV-1 are
different. Such ligand specificity might be responsible for this
differential effect (Rabinovich et al., 2002a; Rabinovich and
Gruppi, 2005).
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bear some significant relevance with respect to primary infec-
tion, considering that intracellular Gal-1 could be released by
sheared fibroblasts and epithelial cells following sex-related
trauma such as micro-abrasions (Akimoto et al., 1995; Baum
et al., 1995). In the context of sexual transmission of HIV-1, the
presence of Gal-1 in the ejaculate could also be an important
factor since Gal-1 has been shown to be present on the heads
and tails of late spermatids in rat testes (Dettin et al., 2003). In
addition, Gal-1 is actively secreted by activated macrophages,
Langerhans cells, dendritic cells, and activated CD4+ and CD8+
T lymphocytes (Blaser et al., 1998; Rabinovich et al., 1996,
1998, 2002b; Reynolds et al., 2007; Zuniga et al., 2001a).
Fibroblasts present at the infection site could also be another
source of Gal-1. Thus, mucosal macrophages could be exposed
to both Gal-1 and R5-tropic HIV-1 particles (Verani et al.,
2005), likely creating a situation that might facilitate and accel-
erate primary infection. Concerning our infection model, even
through Gal-1 is secreted by macrophages, tissular concentra-
tions of Gal-1 could never be reached simply by maintaining
MDMs in culture due to the frequent addition of fresh culture
medium and the fact that the differentiation process does not
lead to the activation of MDMs so that they do not secrete Gal-1
themselves. Moreover, as mentioned earlier, other sources (cells
or sperm) of Gal-1 are normally present in vivo but are absent in
the context of cell culture. Therefore, addition of exogenous
Gal-1 to our infection model is physiologically relevant, in
order to partially reconstitute the initial mucosal infection site
where the presence of extracellular Gal-1 is expected.
This study suggests that Gal-1 increases viral adsorption
kinetics on MDMs, thereby shortening the time required to
establish an infection. During primary infection, the number of
HIV-1 particles is limited. In addition, complement, natural
antibodies and other soluble factors at the primary infection
sites could reduce the infectious potential of the virus (Neil
et al., 2005). Thus, shortening the exposure time required for the
virus to establish an infection would significantly increase the
possibility of a successful HIV-1 infection. Moreover an in-
crease in viral adsorption and entry kinetics reduces the time
required to establish infection and significantly shortens the
crucial period in which post-exposure HAART treatment could
prevent it.
Even in the presence of Gal-1, fusion inhibitors retain their
antiviral potency and display similar IC50 values. These results
confirm that Gal-1 acts mainly at the initial adsorption step, and
not at the fusion-dependent process that would allow HIV-1 to
gain access to the cytoplasm.While fusion inhibitors were potent
inhibitors of HIV-1 infection in MDMs, these drugs could not
efficiently inhibit the inherent ability of MDMs to internalize
large amount of viruses. It has been suggested that following
internalization of HIV-1 within MDMs, HIV-1 could still gain
access to the cytoplasm through fusion of its membrane with the
endosomal membrane. This step remained dependent on gp41
(Marechal et al., 2001) and sensitive to fusion inhibitors such as
T-20. Our data also support the notion that MDMs mainly
internalize HIV-1 through endocytosis, a step that is insensitive
to fusion inhibitors, and are then infected by HIV-1 when itaccesses the cytosol from endosomes in a fusion-dependent
manner. Importantly, despite of the presence of fusion inhibitors,
Gal-1 was still efficient at increasing the amount of internalized
HIV-1 by enhancing initial viral adsorption onto MDMs. In a
situation where the virus is unable to perform fusion (T-20
treated individual), Gal-1 could thus act as a soluble scavenger
receptor and enhance the uptake of the virus bymacrophages. As
those accumulated virions in endosomes are likely to be
degraded and presented in the MHC-II context, the corollary
of these results is that early treatment of patients with fusion
inhibitors could lead to the development of a stronger immune
response towards HIV-1 while limiting viral replication and
spread.
Further investigations are necessary to define whether Gal-1
might act as DC-SIGN, a C-type lectin involved in the endo-
cytosis of HIV-1 that is known to facilitate both HIV-1 antigen-
presentation and viral transmission to CD4+ T lymphocytes
(Geijtenbeek et al., 2000, 2004; Turville et al., 2002, 2004). It
could otherwise be possible that, in the presence of fusion
inhibitors, Gal-1 could act as Langerin, another C-type lectin
found on Langerhans cells, which promotes endocytosis and




Peripheral blood mononuclear cells (PBMCs) were purified
from blood of healthy donors by Ficoll centrifugation (Lym-
phocyte Separation Medium; Wisent Inc.; St-Bruno, QC).
MDMs were produced by incubating PBMCs at a concentration
of 1.25×106 cells in a T-75 flask for 2 h at 37 °C, thus allowing
adhesion of monocytes to the bottom of the flask. Non-adherent
cells were then removed and monocytes were washed twice with
RPMI 1640 containing 5% autologous heat-inactivated plasma
and cultured for 1 week in medium supplemented with 100 ng/
ml macrophage-colony stimulating factor (M-CSF) to allow
differentiation into MDMs. Next, MDMs were detached using
Accutase® (Sigma-Aldrich Inc.; St-Louis, MO) as recom-
mended by the manufacturer and gently scraped with a cell
scraper. MDMs were then dispensed in a 48-well plate at a final
concentration of 5×104 cells per well. Isolation, differentiation
and assays described below were all performed in RPMI 1640
medium containing 5% autologous heat-inactivated plasma.
Viral preparations
Virus particles (NL4-3/BaL) were produced by transiently
transfecting human embryonic kidney 293T cells with the R5-
tropic infectious molecular clone NL4.3BaLenv (kindly sup-
plied by Dr. R.J. Pomerantz, Thomas Jefferson University,
Philadelphia, PA) (Dornadula et al., 1999). The infectious
molecular clone pNL4-3 (X4-tropic) was also used in some
experiments. Recombinant luciferase-encoding reporter R5-
tropic viruses were generated using pNL4-3Luc+Env− (AIDS
Repository Reagent Program, Germantown, MD) and a vector
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Institute, La Jolla, CA) or VSV-G env. Briefly, 2×106 cells were
seeded in a T-75 flask for 24 h before transient transfection,
which was carried out by adding a total of 30 μg of vectors
(pNL4-3/BaL or pNL4-3Luc+Env− and a vector coding for JR-
FL env) to the cells as a calcium phosphate precipitate. At 2 days
post-transfection, the virus-containing supernatant was filtered
and frozen at −85 °C until used. Infectious virus particles were
also prepared from the culture supernatant ofMDMs infected for
3 to 4 weeks using NL4-3/BaL. Titers of virus particles were
normalized by their content of the capsid protein p24 as
determined by a sandwich ELISA or by TCID50 as determined
by testing virus dilution performed on the TZM-BL reporter cell
line (Derdeyn et al., 2000; Platt et al., 1998; Wei et al., 2002)
(obtained through the NIH AIDS Repository Reagent Program;
TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and
Tranzyme, Inc.).
Recombinant galectins
Recombinant galectins were produced and purified as pre-
viously described (Nieminen et al., 2007, 2005; Ouellet et al.,
2005; Pelletier et al., 2003) with the following modifications of
the protocol: lactose was first removed either by using Hiprep
26/10 desalting column (GE Healthcare, Fairfield, Connecticut)
or by extensive dialysis against PBS and the purified galectins
were then passed through Acticlean ETOX endotoxin removing
gels (Sterogene, Carlsbad, California). The purified galectin
preparations were then sterilized by filtration through a 0.22 μm
filter. Mock preparations were also prepared using E. coli
JM109 that does not express Gal-1 using the same purification
protocol. The bioactivities of galectins were estimated by using
a hemagglutinin assay as described previously (Giguere et al.,
2006a,b).
Infection assays
MDMs were infected for 1 h with HIV-1 (1×104 TCID50 of
NL4-3 Luc+Env- pseudotyped with JR-FL env) in the presence
of various concentrations of Gal-1 (ranging from 0 to 4 μM).
Cells were then washed twice with cell culture medium and
incubated for 5 days at 37 °C prior to lysis with 5× lysis buffer
(125 mM Tris phosphate pH 7.8, 10 mM dithiothreitol, 5%
Triton X-100 and 50% glycerol) before measuring luciferase
activity as described previously (Ouellet et al., 1999). For some
experiments, 500 TCID50 of NL4-3/BaL produced by MDMs
was used and p24 levels were estimated by a sandwich ELISA.
Inhibition studies were performed using the fusion inhibitors
T-20 and TAK779 (obtained through the NIH AIDS Repos-
itory Reagent Program).
Virus adsorption and entry assays
MDMs were incubated for 1 h at 37 °C with HIV-1 NL4-3/
Bal (10 ng of p24) in the presence or absence of 2 μMGal-1 and
the fusion inhibitor T-20 or TAK779. Cells were then washed
twice with PBS prior to lysis with 5× lysis buffer (phosphatebuffered saline pH 7.2, 0.05% Tween-20, 2.5% Triton X-100
and 0.02% thimerosal) and the p24 content associated with
MDMs was estimated by ELISA. Entry assays were performed
in a similar manner, except that MDMs were treated with
trypsin (Invitrogen, Carlsbad, CA) for 5 min at 37 °C to remove
uninternalized viruses and washed twice with PBS prior to lysis
as described previously (Tardif and Tremblay, 2005a,b).
LTR activation assay
MDMs were infected 3 days with HIV-1 (5 ng of NL4-3
Luc+Env− pseudotyped with VSV-G env). Cells were then
washed twice prior to adding of 2 μM Gal-1 for 1 to 24 h. Cells
were then lysed with 5× lysis buffer (125 mM Tris phosphate
pH 7.8, 10 mM dithiothreitol, 5% Triton X-100 and 50%
glycerol) before measuring luciferase activity as described
previously (Ouellet et al., 1999). Integrated LTR will respond to
external stimuli and lead to a dose-dependent increase in
luciferase gene transcription and, therefore, activity. TNF-α is
used as a positive control. It is important to note that time course
experiments were performed since gene integration requires an,
as yet, undetermined amount of time.
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